Bicycle Therapeutics (BCYC) vs Perspective Therapeutics (CATX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Perspective Therapeutics (CATX) has outperformed Bicycle Therapeutics (BCYC) over the past year, losing 29.1% versus a loss of 53.4%. Over five years, CATX leads with a -60.3% price change compared with -93.7% for BCYC. Perspective Therapeutics is the larger company by market cap ($277.4 million vs $257.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCYC | CATX |
|---|---|---|
| Share price | $3.68 | $2.43 |
| Market cap | $257.22M | $277.39M |
| 1-day change | -1.47% | -1.22% |
| YTD return | -47.32% | -10.55% |
| 1-year return | -53.37% | -29.11% |
| 5-year return | -93.71% | -60.32% |
| EPS (TTM) | $-2.73 | $-1.33 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.16 | $6.16 |
| 52-week low | $3.33 | $1.96 |
| Distance from 52-week high | -59.88% | -60.55% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +158.50% | +405.76% |
| Average volume | 391.03K | 1.67M |
| Shares outstanding | 50.55M | 114.15M |
| Employees | 288 | 163 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CATX has outperformed BCYC by 24.3 percentage points over the past year.
About Bicycle Therapeutics
BCYC stock →Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing.
Health Care · Biotechnology: Pharmaceutical Preparations · 288 employees
About Perspective Therapeutics
CATX stock →Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha.
Health Care · Biotechnology: Pharmaceutical Preparations · 163 employees
BCYC vs CATX FAQ
Which is bigger, Bicycle Therapeutics or Perspective Therapeutics?
Perspective Therapeutics (CATX) is larger, with a market capitalization of $277.39M compared with $257.22M for Bicycle Therapeutics (BCYC).
Which stock has performed better over the past year, BCYC or CATX?
CATX returned -29.11% over the past 12 months, compared with -53.37% for BCYC (price return, excluding dividends). Past performance does not predict future results.
Are Bicycle Therapeutics and Perspective Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.